盐酸特拉唑嗪联合非那雄胺片对老年良性前列腺增生患者血清TNF－α及PSA水平的影响

摘要

目的：探究盐酸特拉唑嗪联合非那雄胺片对老年良性前列腺增生患者血清肿瘤坏死因子－α（ tumor necrosis factor－α， TNF－α）及前列腺特异抗原（ prostate specific antigen，PSA）水平影响。方法64例老年良性前列腺增生患者根据随机对照表分为对照组和试验组，其中试验组32例，对照组32例，2组均给予常规治疗和对症治疗，对照组给予非那雄胺片；试验组在对照组的基础上联用盐酸特拉唑嗪片。2组患者治疗1个周期，一个周期均为28 d。治疗结束后对比分析2组临床疗效、最大尿流率、前列腺体积、残余尿量、国际前列腺症状（IPSS）评分、TNF－α、PSA水平以及不良反应。结果治疗后2组最大尿流率水平升高（P＜0．05），与对照组相比，试验组最大尿流率水平较高（P＜0．05），2组前列腺体积、残余尿量、国际前列腺症状（IPSS）评分降低（P＜0．05），与对照组相比，试验组上述指标水平较低（P＜0．05）。治疗后2组TNF－α、PSA水平降低（P＜0．05），与对照组相比，试验组TNF－α、PSA水平较低（ P＜0．05）。2组不良反应相比，差异无统计学意义。结论盐酸特拉唑嗪联合非那雄胺片对老年良性前列腺增生患者的临床疗效显著，有效降低血清TNF－α及PSA水平。%Objective To explore the effect of terazosin hydrochloride combined with finasteride on serum TNF-αand PSA in old patients with benign prostatic hyperplasia.Methods 64 elderly patients of benign prostatic hyperplasia were randomly divided into 2 groups, 32 cases in each group.2 groups were given routine treatment and symptomatic treatment, the control group was given finasteride; the experimental group were treated with terazosin hydrochloride combined with finasteride.A cycle of 2 groups were 28 d, a total of 1 cycle of treatment.Clinical efficacy, maximum urinary flow rate, prostate volume, residual urine volume, international prostate symptom score(IPSS), serum tumor necrosis factor alpha, prostate specific antigen level and adverse reactions were compared after the end of treatment.Results Compared with before treatment, maximum urinary flow rate (Qmax) level of 2 groups increased, prostate volume, residual urine volume, international prostate symptom score(IPSS)decreased (P<0.05), compared with the control group, maximum urinary flow rate of the experimental group was higher (P<0.05), prostate volume, residual urine volume, IPSS were lower (P<0.05), 2 groups of TNF-αand PSA levels decreased after treatment (P<0.05), compared with the control group, TNF-αand PSA levels were lower(P<0.05).There was no significant difference in adverse reactions in 2 groups.Conclusion Terazosin hydrochloride combined with finasteride had a clinical efficacy of elderly patients with benign prostatic hyperplasia, can reduce serum TNF-αand PSA levels.